For instance, Hsu et al. used a panel of six methylation markers (BLU, CDH13, FHIT, CDKN2A, RARβ, and RASSF1A genes) on plasma samples from 63 lung cancer patients compared and 36 cancer-free individuals [76]. This evidence concerns the gene CDKN2A and lung carcinoma.